Document Detail


Phospholipase A2 inhibitors for the treatment of inflammatory diseases: a patent review (2010--present).
MedLine Citation:
PMID:  23294257     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Phospholipases A(2) have been implicated in various pathological conditions, such as rheumatoid arthritis, cardiovascular diseases, neurological disorders and cancer. The scientific community focuses on the search of potent and selective PLA(2) inhibitors of each PLA(2) class in order to identify novel medicinal agents. At present, only one lipoprotein-associated PLA(2) (LpPLA(2)) inhibitor has reached Phase III clinical trials for the treatment of atherosclerosis.
AREAS COVERED: This review article focuses on the role of the most important PLA(2)s in inflammatory diseases and other severe pathological conditions presented in patent literature from June 2009 to September 2012.
EXPERT OPINION: Even though the role of each PLA(2) in different diseases or pathological conditions is not yet definitively identified, the progress in the quest for potent and selective PLA(2) inhibitors is exciting and the use of such inhibitors as medicinal agent looks now more promising than ever.
Authors:
Victoria Magrioti; George Kokotos
Related Documents :
24919577 - A review of the pharmacological effects of piceatannol on cardiovascular diseases.
24268527 - Abo histo-blood group might modulate predisposition to crohn's disease and affect disea...
23279867 - Synthesis and biological activity against trypanosoma cruzi of substituted 1,4-naphthoq...
23445907 - Traditional chinese medicine: a promising candidate for the treatment of alzheimer's di...
3118277 - Neonatal screening for metabolic and endocrine diseases.
22142747 - Rare thesaurismosis and xanthomatosis.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2013-01-08
Journal Detail:
Title:  Expert opinion on therapeutic patents     Volume:  23     ISSN:  1744-7674     ISO Abbreviation:  Expert Opin Ther Pat     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-15     Completed Date:  2013-08-09     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  9516419     Medline TA:  Expert Opin Ther Pat     Country:  England    
Other Details:
Languages:  eng     Pagination:  333-44     Citation Subset:  IM    
Affiliation:
Department of Chemistry, Laboratory of Organic Chemistry, University of Athens, Panepistimiopolis, Athens 15771, Greece. vmagriot@chem.uoa.gr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Anti-Inflammatory Agents / pharmacology*,  therapeutic use*
Calcium / physiology
Cytosol / metabolism
Humans
Inflammation / drug therapy*
Lipoproteins / physiology
Phospholipases A2 / metabolism
Receptors, Phospholipase A2 / antagonists & inhibitors*,  metabolism
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Lipoproteins; 0/Receptors, Phospholipase A2; 7440-70-2/Calcium; EC 3.1.1.4/Phospholipases A2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Transbronchial cryo-biopsy in lung transplantation patients: First Report.
Next Document:  Epilepsy after head injury in dogs: A natural model of posttraumatic epilepsy.